KEMPEN PHARMA: what changed
Two financial years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
KEMPEN PHARMA
Largest movements
- Receivables within one year +€370,000
up €370,000 (+586%), from €63,106 to €433,106
- Cash -€44,426
down €44,426 (-70.1%), from €63,396 to €18,970
mainly Receivables within one year (-€370,000) and Debts after one year (-€188,603)
- Reserves +€502,155
up €502,155 (+23.2%), from €2.2m to €2.7m
- Debts after one year -€188,603
down €188,603 (-28.3%), from €665,341 to €476,738
- Financial income +€458,854
up €458,854 (+599%), from €76,563 to €535,417
- Taxes +€44,812
up €44,812 (+61.6%), from €72,801 to €117,613
- Financial charges -€10,975
down €10,975 (-27.1%), from €40,432 to €29,458
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Derived cash bridge
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €3,242,670 | €3,568,497 | +€325,827 | +10.0% |
| Fixed assets | 21/28 | €3,115,779 | €3,115,779 | = | 0.0% |
| Financial fixed assets | 28 | €3,115,779 | €3,115,779 | = | 0.0% |
| Current assets | 29/58 | €126,891 | €452,718 | +€325,827 | +257% |
| Amounts receivable within one year | 40/41 | €63,106 | €433,106 | +€370,000 | +586% |
| Other amounts receivable | 41 | €63,106 | €433,106 | +€370,000 | +586% |
| Cash at bank and in hand | 54/58 | €63,396 | €18,970 | -€44,426 | -70.1% |
| Deferred charges and accrued income | 490/1 | €389 | €642 | +€253 | +64.9% |
| Total equity and liabilities | 10/49 | €3,242,670 | €3,568,497 | +€325,827 | +10.0% |
| Equity | 10/15 | €2,184,318 | €2,686,473 | +€502,155 | +23.0% |
| Contributions | 10/11 | €18,550 | €18,550 | = | 0.0% |
| Reserves | 13 | €2,165,768 | €2,667,923 | +€502,155 | +23.2% |
| Distributable reserves | 133 | €2,165,768 | €2,667,923 | +€502,155 | +23.2% |
| Profit (loss) carried forward | 14 | €0 | €0 | = | |
| Amounts payable | 17/49 | €1,058,352 | €882,024 | -€176,328 | -16.7% |
| Amounts payable after more than one year | 17 | €665,341 | €476,738 | -€188,603 | -28.3% |
| Financial debts | 170/4 | €665,341 | €476,738 | -€188,603 | -28.3% |
| Amounts payable within one year | 42/48 | €387,375 | €400,035 | +€12,659 | +3.3% |
| Current portion of amounts payable after more than one year | 42 | €182,326 | €188,718 | +€6,392 | +3.5% |
| Trade debts | 44 | €0 | €66 | +€66 | |
| Suppliers | 440/4 | €0 | €66 | +€66 | |
| Taxes, remuneration and social security | 45 | €106,280 | €102,842 | -€3,438 | -3.2% |
| Taxes | 450/3 | €106,280 | €102,842 | -€3,438 | -3.2% |
| Other amounts payable | 47/48 | €98,769 | €108,409 | +€9,640 | +9.8% |
| Accrued charges and deferred income | 492/3 | €5,636 | €5,251 | -€385 | -6.8% |
| Other operating charges | 640/8 | €203 | €186 | -€17 | -8.5% |
| Gross operating margin | 9900 | €261,112 | €259,794 | -€1,317 | -0.5% |
| Operating profit (loss) | 9901 | €260,909 | €259,609 | -€1,300 | -0.5% |
| Financial income | 75/76B | €76,563 | €535,417 | +€458,854 | +599% |
| Recurring financial income | 75 | €76,563 | €535,417 | +€458,854 | +599% |
| Financial charges | 65/66B | €40,432 | €29,458 | -€10,975 | -27.1% |
| Recurring financial charges | 65 | €40,432 | €29,458 | -€10,975 | -27.1% |
| Profit (loss) for the period before taxes | 9903 | €297,039 | €765,568 | +€468,529 | +158% |
| Income taxes | 67/77 | €72,801 | €117,613 | +€44,812 | +61.6% |
| Profit (loss) for the period | 9904 | €224,238 | €647,955 | +€423,717 | +189% |
| Profit (loss) for the period to be appropriated | 9905 | €224,238 | €647,955 | +€423,717 | +189% |
Source: filed annual accounts (NBB), financial years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 20 October 2026 via checked.be.